FDA Grants Exemptions to Trading Partners Facing DSCSA Compliance Challenges

In a recent announcement, the FDA provided critical updates for trading partners working toward full compliance with the Drug Supply Chain Security Act (DSCSA). These updates come as the healthcare industry moves toward a fully traceable and secure drug distribution system. The FDA’s newly issued waivers and exemptions offer temporary relief to trading partners who have made documented efforts to meet the enhanced drug distribution security requirements but are still facing challenges in completing their data connections.

Key Takeaways from the FDA's Announcement:

1. ‍Exemptions for Eligible Trading Partners: Trading partners who have either successfully completed or made efforts to establish data connections with their immediate partners may qualify for exemptions. These are temporary extensions designed to prevent disruptions in the drug supply chain and ensure patients continue to receive their medications without delay.
   
   ‍Exemption Durations:
   - Manufacturers and Repackagers: Exemption valid until May 27, 2025.
   - Wholesale Distributors: Exemption valid until August 27, 2025.
   - Dispensers with 26+ Full-Time Employees: Exemption valid until November 27, 2025.
   
   Trading partners eligible for these exemptions do not need to notify the FDA but must continue efforts to meet DSCSA requirements
   ‍
2. ‍‍Small Dispensers Gain Additional Time: The FDA previously granted a separate exemption for small dispensers—pharmacies with 25 or fewer full-time employees licensed as pharmacists or pharmacy technicians. These dispensers still have until November 27, 2026, to fully comply with the enhanced DSCSA requirements.
   
   Small dispensers should determine their eligibility based on employee numbers as of November 27, 2024.
   ‍
3. ‍Requesting Waivers or Exemptions: Trading partners unable to meet the DSCSA deadline of November 27, 2024, may request additional waivers, exceptions, or exemptions. However, submitting a request does not pause the compliance obligation; efforts to meet the requirements must continue until the FDA responds.

This announcement underscores the FDA’s commitment to ensuring a smooth implementation of DSCSA while maintaining critical patient access to medications.

Stay informed and make sure your organization is prepared for the evolving DSCSA landscape!

To read LSPedia's position on the updated guidance, click here.